Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase β is accentuated by BRCA2 mutation (Cancer Research (2010) 70, (409-17) DOI: 10.1158/0008-5472.CAN-09-1353);Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase β is accentuated by BRCA2 mutation

Cancer Research

Volumn 70, Issue 1, 2010, Pages 409-417

  Stachelek, Gregory C ^a   Dalal, Shibani ^a   Donigan, Katherine A ^a   Hegan, Denise Campisi ^a   Sweasy, Joann B ^a   Glazer, Peter M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DNA DIRECTED DNA POLYMERASE BETA; HISTONE H2AX; LITHOCHOLIC ACID; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CHO CELL; CYTOTOXICITY; DNA METHYLATION; DNA REPLICATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXCISION REPAIR; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE STRANDED DNA BREAK;

EID: 75149154678     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0036     Document Type: Erratum

References (48)

1. Ogawa A, Murate T, Suzuki M, Nimura Y, Yoshida S. Lithocholic acid, a putative tumor promoter, inhibits mammalian DNA polymerase β. Jpn J Cancer Res 1998;89:1154-9.
2. Sobol RW, Horton JK, Kuhn R, et al. Requirement of mammalian DNA polymerase-β in base-excision repair. Nature 1996;379:183-6.
3. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004; 38:445-76.
4. Sung JS, Demple B. Roles of base excision repair subpathways in correcting oxidized abasic sites in DNA. FEBS J 2006;273:1620-9.
5. Srivastava DK, Berg BJ, Prasad R, et al. Mammalian abasic site base excision repair. Identification of the reaction sequence and rate-determining steps. J Biol Chem 1998;273:21203-9.
6. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-3.
7. Yung WK. Temozolomide in malignant gliomas. Semin Oncol 2000; 27:27-34.
8. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-51.
9. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
10. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. New Engl J Med 2001;345: 621-2.
11. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-41.
12. Palma JP, Rodriguez LE, Bontcheva-Diaz VD, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008;28:2625-35.
13. Liu X, Shi Y, Guan R, et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008;6:1621-9.
14. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7.
15. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
16. Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet 2006;40:363-83.
17. Liu Y, West SC. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 2002;4:9-13.
18. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-57.
19. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263-72.
20. Lord CJ, Ashworth A. RAD51, BRCA2 and DNA repair: a partial resolution. Nat Struct Mol Biol 2007;14:461-2.
21. Shivji MK, Venkitaraman AR. DNA recombination, chromosomal stability and carcinogenesis: insights into the role of BRCA2. DNA Repair 2004;3:835-43.
22. Krainer M, Silva-Arrieta S, FitzGerald MG, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997;336:1416-21.
23. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet 1998;32:95-121.
24. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13.
25. Weber BH, Brohm M, Stec I, Backe J, Caffier H. A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 1996;59:962-4.
26. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115:523-35.
27. Haracska L, Prakash L, Prakash S. A mechanism for the exclusion of low-fidelity human Y-family DNA polymerases from base excision repair. Genes Dev 2003;17:2777-85.
28. Dalal S, Chikova A, Jaeger J, Sweasy JB. The Leu22Pro tumor-associated variant of DNA polymerase β is dRP lyase deficient. Nucleic Acids Res 2008;36:411-22.
29. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
30. Lang T, Dalal S, Chikova A, DiMaio D, Sweasy JB. The E295K DNA polymerase β gastric cancer-associated variant interferes with base excision repair and induces cellular transformation. Mol Cell Biol 2007;27:5587-96.
31. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temo-zolomide-mediated cell death. Cancer Res 2005;65:6394-400.
32. Wilson SH, Sobol RW, Beard WA, Horton JK, Prasad R, Vande Berg BJ. DNA polymerase β and mammalian base excision repair. Cold Spring Harb Symp Quant Biol 2000;65:143-55.
33. Clairmont CA, Sweasy JB. Dominant negative rat DNA polymerase β mutants interfere with base excision repair in Saccharomyces cerevisiae. J Bacteriol 1996;178:656-61.
34. Cabelof DC, Guo Z, Raffoul JJ, et al. Base excision repair deficiency caused by polymerase β haploinsufficiency: accelerated DNA damage and increased mutational response to carcinogens. Cancer Res 2003;63:5799-807.
35. Dianova II, Sleeth KM, Allinson SL, et al. XRCC1-DNA polymerase β interaction is required for efficient base excision repair. Nucleic Acids Res 2004;32:2550-5.
36. Mizushina Y, Ohkubo T, Sugawara F, Sakaguchi K. Structure of lithocholic acid binding to the N-terminal 8-kDa domain of DNA polymerase β. Biochemistry 2000;39:12606-13.
37. Tentori L, Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 2002;9: 1285-301.
38. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005;577:275-83.
39. Sweasy JB, Lang T, Starcevic D, et al. Expression of DNA polymerase β cancer-associated variants in mouse cells results in cellular transformation. Proc Natl Acad Sci U S A 2005;102:14350-5.
40. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56:783-8.
41. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999;5: 807-14.
42. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
43. King MC,Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
44. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-7.
45. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germ-line mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22:735-42.
46. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007;96:11-5.
47. Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 2002;87:888-91.
48. Rodriguez C, Hughes-Davies L, Valles H, et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 2004;10:5785-91.